334 related articles for article (PubMed ID: 28797122)
21. Crossing the species barrier by PrP(Sc) replication in vitro generates unique infectious prions.
Castilla J; Gonzalez-Romero D; Saá P; Morales R; De Castro J; Soto C
Cell; 2008 Sep; 134(5):757-68. PubMed ID: 18775309
[TBL] [Abstract][Full Text] [Related]
22. Sc237 hamster PrPSc and Sc237-derived mouse PrPSc generated by interspecies in vitro amplification exhibit distinct pathological and biochemical properties in tga20 transgenic mice.
Yoshioka M; Imamura M; Okada H; Shimozaki N; Murayama Y; Yokoyama T; Mohri S
Microbiol Immunol; 2011 May; 55(5):331-40. PubMed ID: 21362027
[TBL] [Abstract][Full Text] [Related]
23. Infrared microspectroscopy detects protein misfolding cyclic amplification (PMCA)-induced conformational alterations in hamster scrapie progeny seeds.
Daus ML; Wagenführ K; Thomzig A; Boerner S; Hermann P; Hermelink A; Beekes M; Lasch P
J Biol Chem; 2013 Dec; 288(49):35068-80. PubMed ID: 24163371
[TBL] [Abstract][Full Text] [Related]
24. Prion encephalopathies of animals and humans.
Prusiner SB
Dev Biol Stand; 1993; 80():31-44. PubMed ID: 8270114
[TBL] [Abstract][Full Text] [Related]
25. Cofactor and glycosylation preferences for in vitro prion conversion are predominantly determined by strain conformation.
Burke CM; Walsh DJ; Mark KMK; Deleault NR; Nishina KA; Agrimi U; Di Bari MA; Supattapone S
PLoS Pathog; 2020 Apr; 16(4):e1008495. PubMed ID: 32294141
[TBL] [Abstract][Full Text] [Related]
26. A new mechanism for transmissible prion diseases.
Makarava N; Kovacs GG; Savtchenko R; Alexeeva I; Ostapchenko VG; Budka H; Rohwer RG; Baskakov IV
J Neurosci; 2012 May; 32(21):7345-55. PubMed ID: 22623680
[TBL] [Abstract][Full Text] [Related]
27. PrP P102L and Nearby Lysine Mutations Promote Spontaneous
Kraus A; Raymond GJ; Race B; Campbell KJ; Hughson AG; Anson KJ; Raymond LD; Caughey B
J Virol; 2017 Nov; 91(21):. PubMed ID: 28835493
[TBL] [Abstract][Full Text] [Related]
28. Transmissible and genetic prion diseases share a common pathway of neurodegeneration.
Hegde RS; Tremblay P; Groth D; DeArmond SJ; Prusiner SB; Lingappa VR
Nature; 1999 Dec; 402(6763):822-6. PubMed ID: 10617204
[TBL] [Abstract][Full Text] [Related]
29. Selective amplification of classical and atypical prions using modified protein misfolding cyclic amplification.
Makarava N; Savtchenko R; Baskakov IV
J Biol Chem; 2013 Jan; 288(1):33-41. PubMed ID: 23168413
[TBL] [Abstract][Full Text] [Related]
30. New Molecular Insight into Mechanism of Evolution of Mammalian Synthetic Prions.
Makarava N; Savtchenko R; Alexeeva I; Rohwer RG; Baskakov IV
Am J Pathol; 2016 Apr; 186(4):1006-14. PubMed ID: 26873446
[TBL] [Abstract][Full Text] [Related]
31. How an Infection of Sheep Revealed Prion Mechanisms in Alzheimer's Disease and Other Neurodegenerative Disorders.
Carlson GA; Prusiner SB
Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34064393
[TBL] [Abstract][Full Text] [Related]
32. Synthetic prions and other human neurodegenerative proteinopathies.
Le NT; Narkiewicz J; Aulić S; Salzano G; Tran HT; Scaini D; Moda F; Giachin G; Legname G
Virus Res; 2015 Sep; 207():25-37. PubMed ID: 25449570
[TBL] [Abstract][Full Text] [Related]
33. Role of Prion Replication in the Strain-dependent Brain Regional Distribution of Prions.
Hu PP; Morales R; Duran-Aniotz C; Moreno-Gonzalez I; Khan U; Soto C
J Biol Chem; 2016 Jun; 291(24):12880-12887. PubMed ID: 27056328
[TBL] [Abstract][Full Text] [Related]
34. Role of prion protein glycosylation in replication of human prions by protein misfolding cyclic amplification.
Camacho MV; Telling G; Kong Q; Gambetti P; Notari S
Lab Invest; 2019 Nov; 99(11):1741-1748. PubMed ID: 31249376
[TBL] [Abstract][Full Text] [Related]
35. Prion infection promotes extensive accumulation of α-synuclein in aged human α-synuclein transgenic mice.
Masliah E; Rockenstein E; Inglis C; Adame A; Bett C; Lucero M; Sigurdson CJ
Prion; 2012; 6(2):184-90. PubMed ID: 22460692
[TBL] [Abstract][Full Text] [Related]
36. Decrease in Skin Prion-Seeding Activity of Prion-Infected Mice Treated with a Compound Against Human and Animal Prions: a First Possible Biomarker for Prion Therapeutics.
Ding M; Teruya K; Zhang W; Lee HW; Yuan J; Oguma A; Foutz A; Camacho MV; Mitchell M; Greenlee JJ; Kong Q; Doh-Ura K; Cui L; Zou WQ
Mol Neurobiol; 2021 Sep; 58(9):4280-4292. PubMed ID: 33983547
[TBL] [Abstract][Full Text] [Related]
37. Prion protein conversion in vitro.
Supattapone S
J Mol Med (Berl); 2004 Jun; 82(6):348-56. PubMed ID: 15014886
[TBL] [Abstract][Full Text] [Related]
38. In vitro evaluation of the anti-prionic activity of newly synthesized congo red derivatives.
Poli G; Ponti W; Carcassola G; Ceciliani F; Colombo L; Dall'Ara P; Gervasoni M; Giannino ML; Martino PA; Pollera C; Villa S; Salmona M
Arzneimittelforschung; 2003; 53(12):875-88. PubMed ID: 14750496
[TBL] [Abstract][Full Text] [Related]
39. An astrocyte cell line that differentially propagates murine prions.
Tahir W; Abdulrahman B; Abdelaziz DH; Thapa S; Walia R; Schätzl HM
J Biol Chem; 2020 Aug; 295(33):11572-11583. PubMed ID: 32561641
[TBL] [Abstract][Full Text] [Related]
40. Sialylation of prion protein controls the rate of prion amplification, the cross-species barrier, the ratio of PrPSc glycoform and prion infectivity.
Katorcha E; Makarava N; Savtchenko R; D'Azzo A; Baskakov IV
PLoS Pathog; 2014 Sep; 10(9):e1004366. PubMed ID: 25211026
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
